Lucica® MI Urinary Myoinositol Kit

Abstract

Diabetes mellitus is a growing healthcare problem internationally, and poses a major burden from both a individual and societal perspective. Diabetes causes potentially life-threatening complications that are preventable if the disease is detected early and appropriate interventions are put in place. Early detection is therefore imperative for preventing diabetes-related morbidity and mortality. Current methods of detection, including the oral glucose tolerance test (OGTT), and measures of fasting plasma glucose, glycated hemoglobin (HbA(1c)), or glycated albumin, can be time-consuming and uncomfortable for patients. Myoinositol can be measured in urine and has been found to be elevated in patients with diabetes and glucose intolerance; it has thus proven useful as a marker for the early detection of these conditions. Lucica MI is a diagnostic kit for the measurement of urinary myoinositol; it is used to detect glucose intolerance and diabetes mellitus at an early stage in disease progression. The test is based on an enzymatic method that uses liquid reagents requiring no preparation. Clinical trial results demonstrate that the test could be used to detect not only diabetes mellitus, but also to distinguish impaired fasting glucose and impaired glucose tolerance from normal glucose tolerance.

Characteristics of individuals who developed type 2 diabetes from prediabetes despite undergoing interventions, and evaluation of the performance of urinary myo‐inositol as a risk factor for developing diabetes

“…was calculated as (Δinsulin [30–0 min] / ΔPG [30–0 min]). The cut‐off values of an FPG of 100 mg/dL (5.6 mmol/L) 3 , an HbA1c of 5.6% (38 mmol/mol) 3 , 4 and a ΔUMI of 10.0 mg/g Cre 16 , which were shown in guidelines and a previous report, were used to determine the positive or negative of each index. The positive was determined when the value was equal to or greater than the cut‐off value, and the negative was determined when the value was less than the cut‐off value.…”

“…Urinary MI (UMI) is known to increase with a decrease in glucose tolerance in the order of healthy individuals, prediabetes, IGT and diabetes, and it is known that the determination of DUMI, the difference between UMI before glucose loading and UMI 120 min after glucose loading during the 75-g OGTT, is useful for identifying patients at high risk of diabetes [12][13][14][15] . We studied the participants with FPG levels of 100-125 mg/dL, and developed the cut-off value of 10 mg/g Cre to detect glucose intolerance with the sensitivity of 93% for diabetes and 68% for IGT 16 . A study by Takakado et al 17 suggested that DUMI could detect mild IGT, because higher blood glucose levels >160-190 mg/dL (8.9-10.5 mmol/L) were associated with an increase in UMI 17 .…”

Comparison of Glycated Hemoglobin (HbA1c) Values Estimated by High-Performance Liquid Chromatography and Spectrophotometry: A Pilot Study

“…These invasive procedures generally reduce patient compliance as they lead to pain, damage to fingers, and risk of infection and measure only instantaneous serum glucose levels rather than long-term glycemic status. The long-term glycemic control is estimated mainly via the glycated fraction of hemoglobin (glycated hemoglobin or HbA1c) and less commonly with other methods such as serum fructosamine [2], glycated albumin [3][4][5], 1,5-anhydro-Dglucitol [6,7] and urinary myoinositol [8]. The HbA1c is a fraction of hemoglobin that comprises around 5% of the total hemoglobin in non-diabetic individuals but up to 15% in patients with diabetes [9].…”